Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
The epidemiology of multiple sclerosis in Europe
2006473 citationsMaura Pugliatti, Giulio Rosati et al.European Journal of Neurologyprofile →
Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial
2019234 citationsGregory L. Krauss, Pavel Klein et al.The Lancet Neurologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Ivan Milanov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Milanov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Milanov more than expected).
This network shows the impact of papers produced by Ivan Milanov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Milanov. The network helps show where Ivan Milanov may publish in the future.
Co-authorship network of co-authors of Ivan Milanov
This figure shows the co-authorship network connecting the top 25 collaborators of Ivan Milanov.
A scholar is included among the top collaborators of Ivan Milanov based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Ivan Milanov. Ivan Milanov is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Krauss, Gregory L., Pavel Klein, Christian Brandt, et al.. (2019). Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. The Lancet Neurology. 19(1). 38–48.234 indexed citations breakdown →
9.
Milanov, Ivan, et al.. (2018). Muscle spasticity and the effects of repetitive Transcranial Magnetic Stimulation in patients with Multiple Sclerosis. SHURA (Sheffield Hallam University Research Archive) (Sheffield Hallam University).1 indexed citations
10.
Winblad, Bengt, M. Fioravanti, Tomáš Doležal, et al.. (2008). Therapeutic Use of Nicergoline. Clinical Drug Investigation. 28(9). 533–552.79 indexed citations
11.
Pugliatti, Maura, Giulio Rosati, H. Carton, et al.. (2006). The epidemiology of multiple sclerosis in Europe. European Journal of Neurology. 13(7). 700–722.473 indexed citations breakdown →
Milanov, Ivan, et al.. (1997). Differential diagnosis of scapuloperoneal syndrome.. PubMed. 37(2). 73–8.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.